GlassScriptPhysician profile
Lea M Lott
NPI 1497251714
$7,056.37
in general payments reported to CMS, 2019-2025
28 companies · $566 in 2025
The $566 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,059 · 2022: $1,239 · 2023: $3,418 · 2024: $773 · 2025: $566.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,226 · Travel and Lodging: $1,507 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,225.64 |
| Travel and Lodging | $1,506.86 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $2,795.51 | 2021-2025 | Xeomin |
| Abbvie INC. | $874.30 | 2021-2024 | |
| Novo Nordisk INC | $805.10 | 2021-2024 | Rybelsus, Ozempic |
| Galderma Laboratories, L.P. | $571.29 | 2022-2025 | Dysport |
| Allergan, INC. | $316.21 | 2021-2022 | |
| Ibsa Pharma INC. | $300.78 | 2021-2025 | Tirosint, Licart, Tirosint |
| Revance Therapeutics, INC. | $257.54 | 2025 | Daxxify |
| Janssen Pharmaceuticals, INC | $168.73 | 2023-2024 | Spravato |
| Currax Pharmaceuticals LLC | $123.67 | 2021-2023 | Nexletol, Onzetra Xsail, Contrave |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $117.73 | 2023-2024 | Xifaxan |
| Nestle Healthcare Nutrition INC. | $105.54 | 2021-2023 | |
| Aimmune Therapeutics, INC. | $94.07 | 2024 | |
| Lilly USA, LLC | $72.84 | 2022-2024 | Zepbound, Mounjaro |
| Amgen INC. | $58.56 | 2021-2023 | Otezla, Repatha |
| Biohaven Pharmaceuticals, INC. | $49.70 | 2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $45.37 | 2024-2025 | Intellis Adaptivestim, Inceptiv |
| Eisai INC. | $40.61 | 2021 | |
| Azurity Pharmaceuticals, INC. | $32.54 | 2023 | Adthyza |
| Arbor Pharmaceuticals, INC. | $30.86 | 2021 | |
| Redhill Biopharma INC. | $30.21 | 2021 | |
| Pfizer INC. | $28.72 | 2023-2024 | |
| Boston Scientific Corporation | $25.92 | 2023 | |
| Glaxosmithkline, LLC. | $24.05 | 2023 | Shingrix, Arexvy |
| Axsome Therapeutics, INC. | $23.68 | 2024 | Auvelity |
| Abbott Laboratories | $17.24 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $16.63 | 2021 | |
| Almatica Pharma LLC | $15.29 | 2022 | |
| Acella Pharmaceuticals, LLC | $13.68 | 2023 | NP Thyroid 60 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lea Lott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.